-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Since the beginning of this year, a large number of pharmaceutical companies are seeking to be listed or have been successfully listed
.
For example, on March 22, Heyuan Biological Science and Technology Innovation Board was listed
.
Its issue price was 13.
23 yuan per share, and the opening price was 20.
70 yuan per share, up 56.
46%
.
As of today's close, it was quoted at 21.
91 yuan per share, up 65.
61%, with a market value of over 10 billion yuan
.
Coincidentally, He's Ophthalmology also officially landed on the Growth Enterprise Market on the same day, becoming the second ophthalmic medical service institution in the A-share market
.
It is understood that He's Ophthalmology will take this IPO as an opportunity to enhance its financial strength, expand its business layout in the country, increase its market share, enhance its market competitiveness, achieve leapfrog development, and further consolidate its advantages in the field of eye health management.
status
.
In addition to the above-mentioned companies, in recent days, a large number of pharmaceutical companies have also started the pace of intensive listing
.
For example, on March 21, Ruike Biotech officially launched an IPO on the Hong Kong Stock Exchange, with a price of HK$24.
80 per share and a first-hand entry fee of HK$12,524.
97.
The IPO time was March 21-24
.
According to the data, Ruike Bio is an innovative vaccine company with a high-value vaccine portfolio driven by self-developed technologies
.
The company mainly focuses on the research and development of HPV vaccine candidates
.
The vaccine portfolio mainly includes 12 vaccines, including the core product REC603, a recombinant HPV nine-valent vaccine currently in the phase III clinical trial stage.
It is one of the few companies in China that has a phase III HPV nine-valent candidate vaccine
.
On March 22, Haichuang Pharmaceutical disclosed the initial public offering of shares and listing on the Science and Technology Innovation Board, the issuance arrangements and the preliminary inquiry announcement, and officially launched the issuance of the Science and Technology Innovation Board.
.
This innovative pharmaceutical company focusing on oncology, metabolic diseases and other therapeutic fields has attracted the attention of the industry for its PROTAC technology layout
.
According to reports, Haichuang Pharmaceutical plans to raise 2,503,958,800 yuan in this new share offering, which will be used for R&D and production base construction projects, innovative drug R&D projects and development reserve funds
.
In addition, according to the "Initial Public Offering of Stocks on the Science and Technology Innovation Board Listing Announcement" previously issued by First Pharmaceutical Holdings, it will also be listed on the Shanghai Stock Exchange on March 23, 2022, at a price of 39.
90 yuan per share
.
In addition, on March 25, the Listing Committee of the Science and Technology Innovation Board will also review the initial application of Shanghai Mengke Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Mengke Pharmaceutical").
An innovative drug company with global independent intellectual property rights and international competitiveness, focusing on sexually transmitted diseases, is committed to the discovery, development and commercialization of innovative drugs for unmet clinical needs
.
.
.
.
For the situation that a large number of companies are rushing to go public, the analysis believes that this is mainly due to the high research and development costs of pharmaceutical companies and the strong uncertainty of future development, so they need strong capital assistance to promote the company's development
.
Therefore, from the current point of view, the track for pharmaceutical companies to seek capitalization process will become more and more hot
.
In the context of the accelerating development of the domestic pharmaceutical industry in the future, the industry expects that pharmaceutical companies will be more welcomed by the capital market, and a large number of pharmaceutical companies will also embark on the road to listing
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
For example, on March 22, Heyuan Biological Science and Technology Innovation Board was listed
.
Its issue price was 13.
23 yuan per share, and the opening price was 20.
70 yuan per share, up 56.
46%
.
As of today's close, it was quoted at 21.
91 yuan per share, up 65.
61%, with a market value of over 10 billion yuan
.
Coincidentally, He's Ophthalmology also officially landed on the Growth Enterprise Market on the same day, becoming the second ophthalmic medical service institution in the A-share market
.
It is understood that He's Ophthalmology will take this IPO as an opportunity to enhance its financial strength, expand its business layout in the country, increase its market share, enhance its market competitiveness, achieve leapfrog development, and further consolidate its advantages in the field of eye health management.
status
.
In addition to the above-mentioned companies, in recent days, a large number of pharmaceutical companies have also started the pace of intensive listing
.
For example, on March 21, Ruike Biotech officially launched an IPO on the Hong Kong Stock Exchange, with a price of HK$24.
80 per share and a first-hand entry fee of HK$12,524.
97.
The IPO time was March 21-24
.
According to the data, Ruike Bio is an innovative vaccine company with a high-value vaccine portfolio driven by self-developed technologies
.
The company mainly focuses on the research and development of HPV vaccine candidates
.
The vaccine portfolio mainly includes 12 vaccines, including the core product REC603, a recombinant HPV nine-valent vaccine currently in the phase III clinical trial stage.
It is one of the few companies in China that has a phase III HPV nine-valent candidate vaccine
.
On March 22, Haichuang Pharmaceutical disclosed the initial public offering of shares and listing on the Science and Technology Innovation Board, the issuance arrangements and the preliminary inquiry announcement, and officially launched the issuance of the Science and Technology Innovation Board.
.
This innovative pharmaceutical company focusing on oncology, metabolic diseases and other therapeutic fields has attracted the attention of the industry for its PROTAC technology layout
.
According to reports, Haichuang Pharmaceutical plans to raise 2,503,958,800 yuan in this new share offering, which will be used for R&D and production base construction projects, innovative drug R&D projects and development reserve funds
.
In addition, according to the "Initial Public Offering of Stocks on the Science and Technology Innovation Board Listing Announcement" previously issued by First Pharmaceutical Holdings, it will also be listed on the Shanghai Stock Exchange on March 23, 2022, at a price of 39.
90 yuan per share
.
In addition, on March 25, the Listing Committee of the Science and Technology Innovation Board will also review the initial application of Shanghai Mengke Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Mengke Pharmaceutical").
An innovative drug company with global independent intellectual property rights and international competitiveness, focusing on sexually transmitted diseases, is committed to the discovery, development and commercialization of innovative drugs for unmet clinical needs
.
.
.
.
For the situation that a large number of companies are rushing to go public, the analysis believes that this is mainly due to the high research and development costs of pharmaceutical companies and the strong uncertainty of future development, so they need strong capital assistance to promote the company's development
.
Therefore, from the current point of view, the track for pharmaceutical companies to seek capitalization process will become more and more hot
.
In the context of the accelerating development of the domestic pharmaceutical industry in the future, the industry expects that pharmaceutical companies will be more welcomed by the capital market, and a large number of pharmaceutical companies will also embark on the road to listing
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
